

## **VIRALEZE™ launch in ADMENTA Italia Group pharmacies in Italy**

- **Starpharma has signed a sales and distribution agreement for VIRALEZE™ with ADMENTA Italia Group, a leader in pharmaceutical retail and wholesale distribution in Italy**
- **ADMENTA operates ~260 pharmacies under its LloydsFarmacia brand (including 13 parapharmacies and 50 franchising pharmacies) in Italy**
- **ADMENTA is also a leading pharmaceutical wholesale distributor in Italy, supplying over 2,500 pharmacies, parapharmacies, drugstores and hospitals through its controlled company FarmAlvarion**
- **ADMENTA is also the Italian holding company of McKesson Europe. McKesson Corporation, USA, is the majority shareholder in McKesson Europe AG. McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology**
- **VIRALEZE™ will be available through ADMENTA's extensive retail pharmacy (LloydsFarmacia) and parapharmacy chains**
- **VIRALEZE™ is a broad-spectrum antiviral nasal spray that contains SPL7013, which has been shown in laboratory studies to have potent antiviral and virucidal activity in multiple respiratory viruses including multiple variants of SARS-CoV-2, where it has been shown to inactivate >99.9% of the Delta variant**

**Melbourne, Australia; 8 October 2021:** Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has signed a sales and distribution agreement for VIRALEZE™ antiviral nasal spray with ADMENTA Italia Group (**ADMENTA**), a leading pharmaceutical retail and wholesale distribution company in Italy. The Italian OTC pharmaceutical market is the third largest in Europe after Germany and the UK.<sup>1</sup>

ADMENTA operates over 260 pharmacies under its LloydsFarmacia brand, including 13 parapharmacies and 50 franchising Pharmacies in Italy.

VIRALEZE™ is expected to be available to Italian consumers in stores and via LloydsFarmacia's [online](#) platform this quarter. Under the agreement, Starpharma will supply VIRALEZE™, with ADMENTA responsible for distribution, sales, and marketing of the product in Italy.

ADMENTA employs around 1,400 people in Italy across both wholesale and retail, supplying over 2,500 pharmacies, parapharmacies, drugstores and hospitals.

VIRALEZE™ is a broad-spectrum antiviral nasal spray, applied in the nose to provide a physical barrier - between viruses and the nasal mucous membrane - that traps and irreversibly inactivates virus, including SARS-CoV-2. The antiviral agent in VIRALEZE™, referred to as SPL7013, has been shown in laboratory studies to have potent antiviral and virucidal activity in multiple respiratory viruses and multiple variants of SARS-CoV-2, including inactivation of >99.9% of the highly infectious [Delta variant](#).

Vincenzo Masci, Marketing & Procurement Director of ADMENTA-LloydsFarmacia commented: "We are delighted to have partnered with Starpharma for VIRALEZE™ antiviral

<sup>1</sup> OTC pharmaceutical sales, Euromonitor 2020

nasal spray in Italy. VIRALEZE™ will be an excellent addition to both our retail and distribution sectors as we head towards winter.”

Dr Jackie Fairley, CEO of Starpharma commented: “We are very pleased to have partnered with ADMENTA in Italy and we look forward to having VIRALEZE™ available soon to Italian consumers, through pharmacies as well as through the leading LloydsFarmacia online platform.”

VIRALEZE™ antiviral nasal spray is registered in Europe and India, and available in certain markets online. In the UK VIRALEZE™ is partnered with LloydsPharmacy, also part of the McKesson group, and Starpharma is in advanced discussions with potential commercial partners elsewhere in Europe, India, Asia and other regions. VIRALEZE™ is not registered for sale or supply in Australia.

#### **ADMENTA Italia Group**

ADMENTA Italia Group, part of McKesson Europe, employs around 1400 people across both wholesale and retail (under the brand LloydsFarmacia), with two distribution centres and over 260 Pharmacies (including 13 Parapharmacies and 50 franchising Pharmacies). ADMENTA also distributes, through its logistic platforms, medical products to 2,500 customers, including pharmacies, parapharmacies, drugstores and hospitals.

[www.admentaitalia.it](http://www.admentaitalia.it) | [www.lloydsfarmacia.it](http://www.lloydsfarmacia.it) | [www.mckesson.eu](http://www.mckesson.eu)

#### **VIRALEZE™ Antiviral Nasal Spray**

VIRALEZE™ contains SPL7013, which has been shown in laboratory studies to inactivate a broad spectrum of respiratory/cold viruses, including multiple SARS-CoV-2 variants, influenza, and RSV. VIRALEZE™ is registered for sale in Europe and India. VIRALEZE™ is not registered for sale or supply in Australia.

SPL7013 is also included in other products registered in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, Australia and New Zealand.

*Starpharma acknowledges the \$1 million in funding for the development of VIRALEZE™ provided by the Australian Government's Medical Research Future Fund (MRFF) Biomedical Translation Bridge (BTB) Program, with support from UniQuest. Delivered by MTPConnect, the Australian Government's BTB program is a \$22.3 million MRFF initiative that provides up to \$1 million in matched funding to nurture the translation of new therapies, technologies and medical devices through to proof of concept to turn innovative medical ideas into reality.*

#### **About Starpharma**

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for respiratory viruses, DEP® drug delivery and VivaGel®. Starpharma has developed VIRALEZE™, an antiviral nasal spray that is registered for sale in the UK/Europe and India, and available in certain markets online. VIRALEZE™ is not approved for sale or supply in Australia. SPL7013 is utilised in approved products - the VivaGel® condom and VivaGel® BV. VivaGel® BV has been licensed in >160 countries, is registered in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, South Africa, Australia and New Zealand.

As a leading company in dendrimer-based drug delivery, Starpharma's proprietary drug delivery platform technology, DEP®, is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP® versions of existing drugs, particularly in the area of anti-cancer therapies. DEP® partnerships include oncology programs with AstraZeneca, with Merck in the area of Antibody Drug Conjugates (ADCs), with Chase Sun in the area of anti-infectives and other world leading pharmaceutical companies. Starpharma's partnered DEP® programs have the potential to generate significant future milestones and royalties.

[Starpharma.com](http://Starpharma.com) | [Twitter](https://twitter.com/Starpharma) | [LinkedIn](https://www.linkedin.com/company/starpharma)

#### **Media: Sumit Media**

Grant Titmus  
Mob: +61 419 388 161  
[grant@sumitmedia.com.au](mailto:grant@sumitmedia.com.au)

#### **Starpharma Holdings Limited**

Dr Jackie Fairley, Chief Executive Officer  
Nigel Baade, CFO and Company Secretary  
+61 3 8532 2704  
[investor.relations@starpharma.com](mailto:investor.relations@starpharma.com)  
4-6 Southampton Crescent  
Abbotsford Vic 3067

#### **Disclosure**

This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.

### Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.